Cargando…

Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly

Myelofibrosis (MF) is a clonal neoplasia of the hemopoietic stem/progenitor cells associated with genetic mutations in the Janus kinase 2 (JAK2), myeloproliferative leukemia virus oncogene (MPL), and calreticulin (CALR) genes. MF is also characterized by a state of chronic inflammation. Calreticulin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sollazzo, Daria, Forte, Dorian, Polverelli, Nicola, Perricone, Margherita, Romano, Marco, Luatti, Simona, Vianelli, Nicola, Cavo, Michele, Palandri, Francesca, Catani, Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031875/ https://www.ncbi.nlm.nih.gov/pubmed/27672242 http://dx.doi.org/10.1155/2016/5860657

Ejemplares similares

Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study
por: Sollazzo, Daria, et al.
Publicado: (2016)

The relevance of a low JAK2(V617F) allele burden in clinical practice: a monocentric study
por: Perricone, Margherita, et al.
Publicado: (2017)

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
por: Barone, Martina, et al.
Publicado: (2020)

The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report
por: Auteri, Giuseppe, et al.
Publicado: (2021)

Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34(+) Cells
por: Forte, Dorian, et al.
Publicado: (2018)

Distinct profile of CD34(+) cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease
por: Forte, Dorian, et al.
Publicado: (2021)

Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
por: Palandri, Francesca, et al.
Publicado: (2012)

How I treat splenomegaly in myelofibrosis
por: Cervantes, F
Publicado: (2011)

Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis
por: Song, Moo-Kon, et al.
Publicado: (2018)

Captopril mitigates splenomegaly and myelofibrosis in the Gata1 (low) murine model of myelofibrosis
por: Corey, Seth J., et al.
Publicado: (2018)

A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia Vera
por: Barone, Martina, et al.
Publicado: (2021)

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2017)

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2022)

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2023)

The “Vesicular Intelligence” Strategy of Blood Cancers
por: Forte, Dorian, et al.
Publicado: (2021)

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2021)

How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation
por: Polverelli, Nicola, et al.
Publicado: (2022)

Sustained response off therapy after fostamatinib: A chronic refractory ITP case report
por: Auteri, Giuseppe, et al.
Publicado: (2023)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
por: Randhawa, Jasleen, et al.
Publicado: (2012)

The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: “Crafting” a Microenvironment That Matters
por: Catani, Lucia, et al.
Publicado: (2021)

Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review
por: Mitra, Debanjali, et al.
Publicado: (2013)

Risk of Immune Thrombocytopenia Relapse and Onset Related to Sars-Cov-2 Infection and Vaccination
por: Auteri, Giuseppe, et al.
Publicado: (2022)

Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study
por: Auteri, Giuseppe, et al.
Publicado: (2023)

Incidence of blast phase in myelofibrosis according to anemia severity
por: Mora, Barbara, et al.
Publicado: (2023)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
por: Palandri, F., et al.
Publicado: (2022)

P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
por: Palandri, Francesca, et al.
Publicado: (2023)

Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?
por: Ciciarello, Marilena, et al.
Publicado: (2021)

P1007: SPLENOMEGALY DEVELOPMENT PRECEDES THE PROGRESS OF HEMATOPOIETIC STEM CELLS MIGRATION TO SPLEEN IN MURINE MYELOFIBROSIS MODELS
por: Kawamura, Toshikuni, et al.
Publicado: (2023)

Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies
por: Palandri, Francesca, et al.
Publicado: (2021)

Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis
por: Farina, Mirko, et al.
Publicado: (2021)

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression
por: Malara, Alessandro, et al.
Publicado: (2022)

P1003: RUXOLITINIB AND MAGROLIMAB INCREASES CALRETICULIN IN MYELOFIBROSIS CD34+ CELLS IN VITRO. PROOF OF CONCEPT FOR COMBINATION THERAPY.
por: Rinaldi, Ciro, et al.
Publicado: (2023)

An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera
por: Barone, Monica, et al.
Publicado: (2021)

Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity
por: Auteri, Giuseppe, et al.
Publicado: (2022)

Primary myelofibrosis evolving to an aplastic appearing marrow
por: Schaefer, Jordan K., et al.
Publicado: (2018)

Splenectomy for Splenomegaly
por: Nixon, J. A.
Publicado: (1913)

Splenomegaly in Britain
por: McNee, J. W.
Publicado: (1929)

Splenomegaly in Britain
por: McNee, J. W.
Publicado: (1929)

Lymphadenopathy and Splenomegaly
por: Lanzkowsky, Philip
Publicado: (2011)

Splenectomy for Splenomegaly
Publicado: (1914)

Cannot write session to /tmp/vufind_sessions/sess_jph5nj3qgc68kl7esm1n22mndi